Mallinckrodt Pharmaceuticals
Where We Aspire to Solve
On July 31, 2025, Mallinckrodt and Endo joined together to better serve patients and customers with a bold plan for the future. Following the merger, the combined company then spun off its generics and sterile injectables business as an independent company—Par Health—and rebranded the specialty therapeutics company as Keenova Therapeutics in November 2025.
Today, Keenova and Par Health operate as separate companies, each with its own mission and identity. Please select the one you would like to visit.